Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for FT836 (CAR T Cell) in Advanced Solid Tumors. The expected timing is based on the latest available company guidance and may change.
05/11/26:- Phase 1 solid tumor study ongoing with trastuzumab and cetuximab; ASGCT poster May 13, 2026. 05/13/26:- Nine patients treated in solid tumor Phase 1; well tolerated. Updated FT836 data expected at ASCO June 2026. 05/21/26:- ASCO 2026 poster presents preliminary Ph1 FT836 solid tumor results on May 30, 2026. 06/01/26:- Preliminary Ph1 FT836 mCRC activity shown; no DLT, CRS, ICANS, or GvHD. Enrollment expanding. 08/13/26:- Ph1 FT836 showed preliminary KRASwt colorectal cancer activity. Next clinical update will occur in H1 2027.
Verification
Confirm timing and program details against the company announcement or filing.